ATE214607T1 - Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose - Google Patents

Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose

Info

Publication number
ATE214607T1
ATE214607T1 AT95903131T AT95903131T ATE214607T1 AT E214607 T1 ATE214607 T1 AT E214607T1 AT 95903131 T AT95903131 T AT 95903131T AT 95903131 T AT95903131 T AT 95903131T AT E214607 T1 ATE214607 T1 AT E214607T1
Authority
AT
Austria
Prior art keywords
myocardial fibrosis
aldosterone antagonists
inhibit myocardial
inhibit
aldosterone
Prior art date
Application number
AT95903131T
Other languages
English (en)
Inventor
Karl T Weber
Original Assignee
Univ Missouri
Karl T Weber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Missouri, Karl T Weber filed Critical Univ Missouri
Application granted granted Critical
Publication of ATE214607T1 publication Critical patent/ATE214607T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95903131T 1993-12-02 1994-12-01 Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose ATE214607T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,236 US5529992A (en) 1992-04-21 1993-12-02 Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
PCT/US1994/013291 WO1995015166A1 (en) 1993-12-02 1994-12-01 Use of aldosterone antagonists to inhibit myocardial fibrosis

Publications (1)

Publication Number Publication Date
ATE214607T1 true ATE214607T1 (de) 2002-04-15

Family

ID=22576080

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903131T ATE214607T1 (de) 1993-12-02 1994-12-01 Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose

Country Status (9)

Country Link
US (3) US5529992A (de)
EP (1) EP0730458B1 (de)
JP (1) JP2916267B2 (de)
AT (1) ATE214607T1 (de)
AU (1) AU703147B2 (de)
CA (1) CA2177848A1 (de)
DE (1) DE69430209T2 (de)
ES (1) ES2173945T3 (de)
WO (1) WO1995015166A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
WO1996040255A2 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
WO1996040256A1 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
AU5349400A (en) * 1995-06-07 2000-10-26 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
AU725689B2 (en) * 1995-06-07 2000-10-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
KR19990022723A (ko) * 1995-06-07 1999-03-25 윌리암스 로저 에이 울혈성심부전의 치료를 위한 스피로노락톤 및 앤지오텐신 ii 길 항제 복합요법
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
CA2390561A1 (en) * 1999-11-09 2001-05-17 Pharmacia Corporation Use of an aldosterone antagonist for treating restenosis
EP1527782A1 (de) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanopartikelzusammensetzungen enthaltend Eplerenon
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
JP3566940B2 (ja) * 2000-04-18 2004-09-15 古河電気工業株式会社 アレイ導波路回折格子型光合分波器
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US20020111337A1 (en) * 2000-08-28 2002-08-15 Fedde Kenton N. Use of an aldosterone receptor antagonist to improve cognitive function
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
CA2469616A1 (en) 2001-12-12 2003-06-19 James W. Aiken Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
WO2004073602A2 (en) * 2002-01-25 2004-09-02 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US20030199483A1 (en) * 2002-01-30 2003-10-23 Mcmahon Ellen G. Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US20040102375A1 (en) * 2002-05-15 2004-05-27 Massachusetts Institute Of Technology Methods to overcome inhibition of growth cone translocation
DK1537114T3 (da) * 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
JP2005536536A (ja) * 2002-08-23 2005-12-02 ファルマシア コーポレイション アルドステロンブロッカーによるマトリックスメタロプロテイナーゼ（ｍｍｐ）活性のモジュレーション
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
CN100447142C (zh) * 2002-11-18 2008-12-31 诺瓦提斯公司 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
MX2008015008A (es) * 2006-05-26 2008-12-05 Novartis Ag INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
CA2660701A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
AU2015258805B2 (en) * 2014-05-16 2018-05-10 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003996A (en) * 1974-09-09 1977-01-18 G. D. Searle & Co. Spirolactone for inhibiting the cardiotoxic effects of adriamycin

Also Published As

Publication number Publication date
EP0730458A1 (de) 1996-09-11
JPH09508354A (ja) 1997-08-26
EP0730458B1 (de) 2002-03-20
CA2177848A1 (en) 1995-06-08
US5668124A (en) 1997-09-16
DE69430209D1 (de) 2002-04-25
JP2916267B2 (ja) 1999-07-05
US5668125A (en) 1997-09-16
DE69430209T2 (de) 2002-12-12
WO1995015166A1 (en) 1995-06-08
AU703147B2 (en) 1999-03-18
US5529992A (en) 1996-06-25
ES2173945T3 (es) 2002-11-01
AU1210695A (en) 1995-06-19

Similar Documents

Publication Publication Date Title
ATE214607T1 (de) Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose
ATE416772T1 (de) Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
EP0437103A3 (de) Substituierte 5-(Alkyl)-carboxamid-Imidazole
AU640417B2 (en) Substituted 5-((tetrazolyl)alkenyl)imidazoles
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
EP0403158A3 (de) Imidazolyl-Alkensäuren
MX9803992A (es) Metodos para incrementar la masa de tejido muscular usando composiciones de la proteina ob.
MY110205A (en) Imidazolyl-alkenoic acids.
ATE98245T1 (de) Azaindene.
BG101384A (en) New pesticide proteins and strains
HU9902075D0 (en) Angiotensin ii receptor blocking imidazole derivatives and pharmaceutical compositions containing them as active ingredients
ATE238800T1 (de) Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DK5389A (da) Substituerede pyrroler, pyrazoler og triazoler, fremgangsmaader til deres fremstilling samt deres anvendelse som angiotensin ii-antagonister
EE200100146A (et) Alfa-4 subühikut kandva integriini ja alfa-4 subühikut kandva integriini ligandi vahelise interaktsiooni antagonisti kasutamine
MX9710392A (es) Antagonistas de receptores de vitronectina, su preparacion asi como su empleo.
MY106159A (en) Substituted n-(imidazolyl)alkyl alanine derivatives.
CA2237189A1 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
WO2000028020A3 (en) Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
DE69616944D1 (de) Verwendung von des-aspartat-angiotensin i als wirkstoff gegen herzhypertrophie
WO1993020839A3 (en) Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
WO1990007321A3 (en) Lymphocyte receptor homing sequences and their uses
EP0995430A3 (de) Verwendung von Wirkstoffen, gewählt aus der Gruppe der 1,2-Diacylglycerole, zur Stärkung der Barrierefunktion der Haut

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties